Key Takeaways
- Moderna rejoined the Nasdaq-100 this morning. The vaccine maker (MRNA) re-entered the index of the 100 biggest Nasdaq non-financial companies before Friday's open, replacing Warner Bros. Discovery, which left after being taken over.
- It's a genuine redemption story. Moderna was kicked OUT of this same index in December 2024 after its market value collapsed. Twenty-two months later it's back, up roughly 650% in a year and touching a 52-week high above $212 today.
- Index inclusion has real mechanics. More than 200 investment products with over $800 billion track the Nasdaq-100. When a stock joins, those funds must buy it. If you hold a Nasdaq-100 fund, you became a Moderna owner this morning without lifting a finger.
- Two big dates loom: cancer-vaccine (melanoma) data on 24 October, and earnings on 29 October. The comeback's next chapters are already scheduled.
- The honest catch: joining an index is a flow, not a verdict. Moderna is still loss-making, at least one major bank rates it Sell, and the same door it just walked through ejected it two years ago.
- Research it your way: you can invest in global stocks and ETFs from just $1 with zero commission on the Nemo.money app.
Introduction
Two years ago, Moderna was the market's cautionary tale. The COVID-vaccine fortune had evaporated, the stock had collapsed, and in December 2024 the Nasdaq-100 showed it the door.
This morning, it walked back in.
Moderna rejoined the index of the Nasdaq's 100 biggest non-financial companies before Friday's open, with its shares at a 52-week high and up roughly 650% over the past year, one of the great comeback trades of 2026. And because hundreds of billions of dollars blindly track that index, thousands of ordinary investors became Moderna shareholders today without doing a thing.
That last part is the real story. Index changes look like housekeeping, but they move real money, and understanding how is one of the most useful things an everyday investor can learn. This guide covers the comeback, today's mechanics, the two big dates ahead, and the honest catches. It's educational, not investment advice. To explore the theme, you can invest in global stocks and ETFs from just $1 with zero commission on the Nemo.money app.
People are searching:
- "Moderna Nasdaq 100"
- "MRNA stock"
- "why is Moderna stock up"
- "Moderna comeback"
- "what happens when a stock joins an index"
- "Moderna cancer vaccine"
- "Moderna stock forecast"
What Happened Today
- 📅 The change: before Friday's open, Moderna (MRNA) became a component of the Nasdaq-100, per Nasdaq's 1 October announcement. It replaces Warner Bros. Discovery, which exits the index after Paramount-Skydance completed its acquisition of the studio this week.
- 🔄 Why "rejoined" is the right word: Moderna was removed from the Nasdaq-100 in December 2024, when its post-COVID collapse had shrunk it below the cut. Index membership is rented, not owned, in both directions.
- 📈 The stock's day: MRNA touched a 52-week high of $212.53 this morning, up around 2-3% in early trading after a strong run into the event, valuing the company near $82 billion.
- 🧮 The run-up was partly mechanical: between the 1 October announcement and today, index-tracking funds had to position for forced buying, one reason the shares climbed from about $189 to over $210 in a week. The event was known; the money moved ahead of it.
The Comeback: Boom, Bust, Rebuild
Moderna's journey is a whole market cycle in one ticker:
- 🚀 The boom: COVID made Moderna a household name and, briefly, one of the world's most valuable biotechs. Then demand faded, revenue fell off a cliff, and the shares lost most of their value.
- 📉 The bust's low point: by late 2024 the fall had carried it out of the Nasdaq-100 altogether. Analysts wrote it off as a one-product story whose product had expired.
- 🧬 The rebuild: Moderna bet its mRNA platform could outlive COVID, flu programmes, and above all cancer: personalised vaccines designed from a patient's own tumour. That bet hit in August, when a landmark melanoma trial with Merck succeeded and the stock more than doubled, which we covered at the time. The same month it raised $2.6 billion in convertible notes partly to fund the oncology push.
- 📈 The 2026 verdict so far: the market has repriced the pipeline dramatically, the stock is up roughly 650% over twelve months, it was "only" up 392% when we last checked in on the rally in August. That's the run today's index entry certifies.
- 🗓️ And the next test is already scheduled: melanoma (skin-cancer) vaccine data lands on 24 October, with earnings on 29 October. The comeback is still being graded, in public, this month.
What Index Inclusion Actually Does
This is the lesson worth keeping long after the headline fades:
- 🏦 Index funds don't choose, they copy. More than 200 investment products with over $800 billion in assets track the Nasdaq-100. When the index adds a stock, every one of them must buy it, automatically, at whatever the price is. That's called mechanical demand, and it's real money.
- 👤 Which means: you may own Moderna now. If you hold a Nasdaq-100 fund, QQQ, which we've mapped in full, a slice of your money became Moderna this morning. No action needed, no notification sent.
- 🧭 It was already true elsewhere: Moderna has sat in the S&P 500 for years, so holders of broad funds, like VOO, which our beginner's guide covers, owned it through the entire bust and rebound. Index investing means owning the whole drama, not just the hits.
- ⚖️ But inclusion is arithmetic, not approval. A stock joins because it got big enough, that's all. The index committee isn't saying "good company". It's saying "large company". Those are different things, as Moderna's own 2024 ejection proved.
The Other Side of the Door: Why Warner Bros. Left
- 🎬 Moderna's seat was vacated by a takeover. Warner Bros. Discovery exits the Nasdaq-100 because Paramount-Skydance's acquisition of the studio completed this week. Companies leave indexes when they shrink, move, or get bought, and 2026's deal wave has been pulling names out of benchmarks all year.
- 🔄 Index churn tells you what the market is becoming. A film studio leaves; a vaccine-and-cancer-biotech enters. Repeat that across every change this year, AI firms in, acquired and shrunken firms out, and you can watch the index quietly morph into a different animal. The Nasdaq-100 of 2026 is not the one you learned in 2020.
- 📋 For index-fund holders, this is the deal you signed: your holdings update themselves. That's mostly a feature, you always own the current giants, but it's worth glancing at the passenger list occasionally. It changes more than people think.
The Honest Catch
- 🚪 The same door swings both ways. Moderna is rejoining the index that ejected it 22 months ago. If the comeback falters, nothing stops a second exit. Membership certifies size today, not success tomorrow.
- 💸 It's still losing money. The revival is a pipeline story: Moderna's operating profile remains loss-making, and the rally prices in trials that haven't read out yet. The 24 October melanoma data is close to a binary event, good news could extend the run, bad news could cut it sharply.
- 🐻 Not everyone's convinced: at least one major bank, Citi, carries a Sell rating even as the stock sits at a 52-week high. After a 650% year, the easy part of the comeback, if there was one, is behind.
- 🌀 Inclusion pops often fade. The mechanical buying around index entry is a one-time adjustment. Once the funds are positioned, that demand is spent, and the stock trades on fundamentals again. Chasing a stock because it joined an index mistakes a flow for a reason.
- 🧪 Biotech volatility is its own league. This is a company whose value quadrupled-plus in a year after losing most of it in the two before. Position sizes should respect that history.
The takeaway: a real comeback, a real index milestone, and a stock whose next three weeks of scheduled events matter more than today's ceremony.
What It Means for You
- 🧭 Check your passenger list. If you hold index funds, today changed what you own. Knowing the big names inside your funds, and when they change, is basic hygiene most investors skip.
- 📊 Learn the flows-vs-verdicts rule. Index inclusion, fund rebalancing and forced buying move prices without saying anything about value. When a stock jumps, always ask: fundamentals, or plumbing?
- 🗓️ Mark the dates: 24 October (melanoma data) and 29 October (earnings). If you're researching Moderna at all, those two days will teach you more than today did.
How to Research Moderna with Nemo.money
The Nemo.money app is built to help you research before you decide:
- Invest from Just $1: Fractional investing lets you explore MRNA or any US-listed stock without big commitments, sensible for a name this volatile.
- Zero-Commission Trading: Buy and sell US-market stocks and ETFs without commission fees.
- AI-Powered Insights & Nemes: Explore data, sentiment and curated themed collections (Nemes) as a research starting point (for research, not recommendations).
- Earn 6% AER on Idle Cash: Uninvested cash in your wallet earns 6% AER, paid daily in USD, while you research and decide.
Frequently Asked Questions (FAQs)
Why did Moderna join the Nasdaq-100?
Because it got big enough again. Nasdaq announced on 1 October that Moderna would replace Warner Bros. Discovery, which left the index after Paramount-Skydance completed its acquisition. Moderna had been removed from the same index in December 2024 when its market value collapsed; a roughly 650% one-year rally carried it back.
What happens when a stock joins a major index?
Funds that track the index, more than 200 products with over $800 billion follow the Nasdaq-100, must buy the stock to mirror the benchmark. That creates one-time mechanical demand around the change, which is why inclusion announcements often move prices before the effective date. It is a flow, not a judgement of the company's value.
Is Moderna profitable now?
No. Moderna's operations remain loss-making; the 2026 rally reflects optimism about its pipeline, particularly personalised cancer vaccines, rather than current profits. Key upcoming tests are the melanoma data due 24 October and earnings on 29 October.
Is Moderna stock a good buy after this rally?
That's a personal research decision with honest arguments both ways. For: a revived pipeline, major cancer-vaccine catalysts ahead, fresh index-fund ownership, and $2.6 billion raised for the oncology push. Against: still unprofitable, up ~650% already, at least one major bank rates it Sell, imminent binary trial data, and a history of extreme swings in both directions.
How can I invest in Moderna from the UAE?
Moderna trades on the Nasdaq under the ticker MRNA. On the Nemo.money app you can research and invest in eligible US-listed stocks and ETFs from $1 with zero commission, with uninvested cash earning 6% AER, paid daily in USD, while you decide.
Final Thoughts: Comebacks Get Certified, Not Finished
Today Moderna got its seat back at the big table. That's worth marking, two years ago, this company was the market's favourite example of a boom gone wrong, and the recovery from there to a 52-week high is genuinely rare.
But notice what today's ceremony actually was: arithmetic. The index measured Moderna's size and updated its list. The questions that matter, does the cancer-vaccine data deliver on the 24th, do the earnings hold up on the 29th, can a loss-making pipeline justify a 650% year, were not answered this morning. They're scheduled for the next three weeks.
So enjoy the comeback story. Learn the index mechanics, they'll serve you forever. And remember that the market hands out seats, not verdicts. Verdicts come from results.
Explore global stocks and ETFs from $1 with zero commission on the Nemo.money app.
Nemo = Never Miss Out.
Stay informed. Stay ahead.
#Moderna #Nasdaq100 #Biotech #StockMarket #Investing #NemoMoney
Terms and conditions apply. This is not investment advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.
